Clinical Trials Sponsored by Aevi Genomic Medicine, LLC, a Cerecor company

Total 12 results

Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

22q11.2 Deletion Syndrome

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Acute Lung Injury | ARDS | COVID-19 Pneumonia

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd.

Terminated

TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)

Anemia of End Stage Renal Disease

Israel
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd.

Completed

TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)

End Stage Renal Disease | Chronic Kidney Disease

Israel
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd.

Terminated

TARGTEPO Treatment for Anemia in PD US Trial

Anemia of End Stage Renal Disease

United States
Aevi Genomic Medicine, LLC, a Cerecor company
Children's Hospital of Philadelphia; Thomas Jefferson University; Pearson/Clinical...

Completed

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder (NFC1-GREAT)

Attention-deficit Hyperactivity Disorder (ADHD)

United States

Clinical Trials Sponsored by Aevi Genomic Medicine, LLC, a Cerecor company

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations